1981
The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture
Devita V. The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture. Cancer 1981, 47: 1-13. PMID: 6970069, DOI: 10.1002/1097-0142(19810101)47:1<1::aid-cncr2820470102>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseLong-term adverse consequencesPresence of symptomsNational Cancer InstituteMOPP programComplete remissionNodular sclerosisHistologic subtypeImmunosuppressive drugsNational mortalityEffective chemotherapyDrug treatmentCancer InstituteChemotherapyDiseaseCarcinogenic effectsAdverse effectsYoung populationMOPPAdverse consequencesImportant negative influenceRemissionSclerosisPatientsPrognosis
1980
Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease.
Fisher R, DeVita V, Bostick F, Vanhaelen C, Howser D, Hubbard S, Young R. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Annals Of Internal Medicine 1980, 92: 595-9. PMID: 6992672, DOI: 10.7326/0003-4819-92-5-595.Peer-Reviewed Original ResearchConceptsLong-term survivorsMitogen-induced lymphocyte proliferationPersistent immunologic abnormalitiesHodgkin's diseaseImmunologic abnormalitiesE rosettesLymphocyte proliferationAdvanced diffuse histiocytic lymphomaDepressed cellular immunityAdvanced Hodgkin's diseaseDisease-free intervalDiffuse histiocytic lymphomaB cell numbersNormal control subjectsComparable chemotherapyMOPP chemotherapyUntreated patientsCellular immunityControl subjectsHistiocytic lymphomaImmunologic studiesNormal rangeControl populationChemotherapyAbnormalities